Referencia número: HY-N0622

Morusin

(Synonyms: Mulberrochromene)

14 Cited Publications

Revisión del cliente

Based on 14 publication(s) in Google Scholar

Morusin is a prenylated flavonoid isolated from Morus alba Linn. with various biological activities, such as antitumor, antioxidant, and anti-bacteria property. Morusin could inhibit NF-κB and STAT3 activity.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza: 99.54%
No. CAS: 62596-29-6
Fòrmula: C₂₅H₂₄O₆
Peso molecular:420.45

Almacenamiento:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Morusin Chemical Structure

No. CAS: 62596-29-6

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (14)
Solvente y solubilidad
- In Vitro
- In Vivo
Protocolo
Pureza y Documentación
Referencias
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

IC₅₀ & Target^[1]^[3]

p65

STAT3

Ver todos los productos específicos de isoformas NF-κB :

Ver todos los productos específicos de isoformas STAT :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	24.09 μM Compound: 5	Cytotoxicity against human A549 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay	[PMID: 27400887]
Bcap37	IC₅₀	33.1 μM Compound: 5	Cytotoxicity against human Bcap37 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human Bcap37 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay	[PMID: 27400887]
Calu-3	CC₅₀	25.2 μM Compound: 23	Cytotoxicity against human Calu-3 cells assessed as reduction in cell viability Cytotoxicity against human Calu-3 cells assessed as reduction in cell viability	[PMID: 36651644]
HEK293	IC₅₀	59.4 μM Compound: 3	Inhibition of human recombinant BACE-1 expressed in HEK293 cells assessed as inhibition of amyloid precursor protein cleavage into amyloid beta after 60 mins using Rh-EVNLDAEFK-Quencher as a substrate by FRET assay Inhibition of human recombinant BACE-1 expressed in HEK293 cells assessed as inhibition of amyloid precursor protein cleavage into amyloid beta after 60 mins using Rh-EVNLDAEFK-Quencher as a substrate by FRET assay	[PMID: 21511472]
HepG2	IC₅₀	9.3 μM Compound: 5	Cytotoxicity against human HepG2 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay	[PMID: 27400887]
LN-18	IC₅₀	24 μM Compound: Moursin	Cytotoxicity against human LN18 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human LN18 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 26829656]
MCF7	IC₅₀	11.51 μM Compound: 5	Cytotoxicity against human MCF7 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay	[PMID: 27400887]
RAW264.7	IC₅₀	>12.5 μg/mL Compound: 9	Inhibition of LPS-induced NO production in mouse RAW264.7 cells measured after 24 hrs by Griess assay Inhibition of LPS-induced NO production in mouse RAW264.7 cells measured after 24 hrs by Griess assay	[PMID: 27908762]
SR	IC₅₀	43.57 μM Compound: Morusin	Inhibition of SERCA1 in NewZealand rabbit skeletal muscle SR vesicles using ATP as substrate incubated for 2 mins followed by Ca2+ addition by NADH coupled enzyme assay Inhibition of SERCA1 in NewZealand rabbit skeletal muscle SR vesicles using ATP as substrate incubated for 2 mins followed by Ca2+ addition by NADH coupled enzyme assay	[PMID: 32435418]
T98G	IC₅₀	24 μM Compound: Moursin	Cytotoxicity against human T98G cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human T98G cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 26829656]
U138-MG	IC₅₀	24 μM Compound: Moursin	Cytotoxicity against human U138MG cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human U138MG cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 26829656]
U-251	IC₅₀	17.95 μM Compound: 5	Cytotoxicity against human U251 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human U251 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay	[PMID: 27400887]
U-251	IC₅₀	24 μM Compound: Moursin	Cytotoxicity against human U251MG cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human U251MG cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 26829656]
U-373MG ATCC	IC₅₀	24 μM Compound: Moursin	Cytotoxicity against human U373MG cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human U373MG cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 26829656]
U-87MG ATCC	IC₅₀	24 μM Compound: Moursin	Cytotoxicity against human U87MG cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human U87MG cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 26829656]

In Vitro

Morusin exhibits a dose- and time-dependent inhibitory effect on murine and human breast cancer cells. IC₅₀ is 9.48 μg/mL for normal mammary epithelial cells (MCF-10A); 2.03 and 1.87 μg/mL for murine breast cancer cells (4 T1 and EMT6); and 2.71 and 3.86 μg/mL for human breast cancer cells (MCF-7 and MDA-MB-231), respectively, the maximal inhibition of cell growth (>80 %) is obtained at 8 μg/mL. The apoptotic cells in morusin treated breast cancer cells are increased significantly in a dose-dependent manner^[1]. Morusin significantly inhibits the growth and clonogenicity of human colorectal cancer HT-29 cells. Morusin also inhibits the phosphorylation of IKK-α, IKK-βand IκB-β, increases expression of IκB-α, and suppresses nuclear translocation of NF-κB and its DNA binding activity. Dephosphorylation of NF-κB upstream regulators PI3K, Akt and PDK1 is also displayed. In addition, activation of caspase-8, change of mitochondrial membrane potential, release of cytochrome c and Smac/DIABLO, and activation of caspase-9 and -3 are observed at the early time point. Downregulation in the expression of Ku70 and XIAP is exhibited afterward^[2]. Morusin suppresses viability of prostate cancer cells, but little effect in normal human prostate epithelial cells. Morusin also reduces STAT3 activity by inhibiting its phosphorylation, nuclear accumulation, and DNA binding activity. In addition, morusin down-regulated expression of STAT3 target genes encoding Bcl-xL, Bcl-2, Survivin, c-Myc and Cyclin D1. It induces apoptosis in human prostate cancer cells by reducing STAT3 activity^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Morusin retards the growth of breast cancer significantly. Mean tumor weight of the control mice is 1.14±0.30 g, and those of the mice administrated with 5 and 10 mg/kg of morusin are 0.61±0.23 and 0.41±0.10 g, respectively, tumor inhibitory rates are 46.5 %, and 64.1 %, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

No. CAS 62596-29-6
Appearance Solid
Peso molecular 420.45
Fòrmula C₂₅H₂₄O₆
Color Light yellow to yellow
SMILES

O=C1C2=C(O)C=C3C(C=CC(C)(C)O3)=C2OC(C4=CC=C(O)C=C4O)=C1C/C=C(C)\C
Synonyms

Mulberrochromene
Structure Classification
- Flavonoids
- Flavones
- Phenols
- Polyphenols
Initial Source
- Plants
- other families
Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (14)

All WB

Sort by:

Journal Impact Factor

Phytomedicine

Morusin ameliorates tubulointerstitial damage in diabetic mice through SIRT1/HIF-1α/IL-16 signaling pathway. [Abstract]

2025 Jul:142:156781. PMID: 40382816
Food Chem

Effects of sun drying combined with baking processes on the flavor quality of Chongqing Tuocha raw tea. [Abstract]

2025 Dec 30:497:146992. PMID: 41285060
Food Chem

Flavonoid-mediated metabolic underpinning quality variation in red bud-sport pear mutants. [Abstract]

2025 May 31:489:144992. PMID: 40466530
Phytother Res

Morusin Alleviates Spinal Cord Injury in Rats by Regulating Macrophage Reprogramming Through Targeting RELA and NRF2. [Abstract]

2025 Dec 2. PMID: 41331897
Stem Cell Res Ther

Morusin induces osteogenic differentiation of bone marrow mesenchymal stem cells by canonical Wnt/β-catenin pathway and prevents bone loss in an ovariectomized rat model. [Abstract]

2021 Mar 12;12(1):173. PMID: 33712069

Morusin purchased from MedChemExpress. Usage Cited in: Stem Cell Res Ther. 2021 Mar 12;12(1):173. [Abstract]

Stimulated mRNAs expression of Col1a1, Runx2, and Bsp is detected in BMSCs disposed with 2.5, 5, and 10 μM of Morusin for 3, 5, and 7 days, in comparison to the control group. COL1A1 and RUNX2 protein expression is found increased in osteogenic BMSCs with Morusin at days 3, 5, and 7.
Food Funct

Protective effects of a herbal combination (Dimocarpus longan and Orthosiphon stamineus) on metabolic-associated fatty liver disease via the ERα-PI3K-AKT pathway. [Abstract]

2026 Feb 23. PMID: 41729581
Drug Des Devel Ther

Morusin Ameliorates IL-1β-Induced Chondrocyte Inflammation and Osteoarthritis via NF-κB Signal Pathway. [Abstract]

2020 Mar 26;14:1227-1240. PMID: 32273685
J Cell Mol Med

Integrated Network Pharmacology, Single-Cell Transcriptomics Unveil the Mechanistic Role of Morusin in Aortic Dissection. [Abstract]

2026 Jan;30(1):e70971. PMID: 41482800
Naunyn Schmiedebergs Arch Pharmacol

Morusin attenuates myocardial ischemia/reperfusion injury by inhibiting ferroptosis via dual activation of the Nrf2/HO-1 pathway and mTORC1-dependent GPX4 synthesis. [Abstract]

2026 Jan 15. PMID: 41538060
Chem Biol Drug Des

Morusin Reverses Epithelial-Mesenchymal Transition in Gallbladder Cancer Cells by Regulating STAT3/HIF-1α Signaling. [Abstract]

2025 Jan;105(1):e70054. PMID: 39825622
Vet Microbiol

Identification and evaluation of Nordihydroguaiaretic acid (NDGA) as an active traditional Chinese medicine compound inhibiting the 3C-like protease of feline infectious peritonitis virus. [Abstract]

2025 Sep 15:310:110730. PMID: 40976146
Biochem Biophys Res Commun

Effects of intracellular iron overload on cell death and identification of potent cell death inhibitors. [Abstract]

2018 Sep 3;503(1):297-303. PMID: 29890135
bioRxiv

2025 Jan 03.
Ann Transl Med

Morusin exerts anti-cancer activity in renal cell carcinoma by disturbing MAPK signaling pathways. [Abstract]

2020 Mar;8(6):327. PMID: 32355771

Solvente y solubilidad

In Vitro:

DMSO : ≥ 100 mg/mL (237.84 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.3784 mL

11.8920 mL

23.7840 mL

5 mM

0.4757 mL

2.3784 mL

4.7568 mL

10 mM

0.2378 mL

1.1892 mL

2.3784 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.95 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (5.95 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocolo

Cell Assay^[1]

The cytotoxicity of morusin against human normal mammary epithelial cells and murine breast cancer cells (4 T1 and EMT6) and human breast cancer cells (MCF-7 and MDA-MB-231) is tested by modified MTT assay [23]. Cells are treated with various concentrations of morusin (1, 2, 4, 6 and 8 μg/mL). After treatment with morusin for 1, 2, 3, 4, and 5 days, 20 μL MTT (pH 4.7) is added to each well, and cultivated for another 4 h, 100 μL of 10 % SDS/0.01 N HCl is added and incubated at 37 °C overnight to dissolve the formazan. Absorbance is measured at 570 nm^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]

Mice: Two treatment group mice are injected with 5 and 10 mg/kg of morusin i.p. three times weekly for 4 weeks, respectively, and the control mice are injected with DMSO. During the experiment, mice are weighted, and tumor volumes are measured weekly using calipers and their volumes are calculated^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (284 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Li H, et al. Morusin suppresses breast cancer cell growth in vitro and in vivo through C/EBPβ and PPARγ mediated lipoapoptosis. J Exp Clin Cancer Res. 2015 Nov 4;34:137. [Content Brief]

[2]. Lee JC, et al. Morusin induces apoptosis and suppresses NF-kappaB activity in human colorectal cancer HT-29 cells. Biochem Biophys Res Commun. 2008 Jul 18;372(1):236-42. [Content Brief]

[3]. Lim SL, et al. Morusin induces cell death through inactivating STAT3 signaling in prostate cancer cells. Am J Cancer Res. 2014 Dec 15;5(1):289-99. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.3784 mL	11.8920 mL	23.7840 mL	59.4601 mL
	5 mM	0.4757 mL	2.3784 mL	4.7568 mL	11.8920 mL
	10 mM	0.2378 mL	1.1892 mL	2.3784 mL	5.9460 mL
	15 mM	0.1586 mL	0.7928 mL	1.5856 mL	3.9640 mL
	20 mM	0.1189 mL	0.5946 mL	1.1892 mL	2.9730 mL
	25 mM	0.0951 mL	0.4757 mL	0.9514 mL	2.3784 mL
	30 mM	0.0793 mL	0.3964 mL	0.7928 mL	1.9820 mL
	40 mM	0.0595 mL	0.2973 mL	0.5946 mL	1.4865 mL
	50 mM	0.0476 mL	0.2378 mL	0.4757 mL	1.1892 mL
	60 mM	0.0396 mL	0.1982 mL	0.3964 mL	0.9910 mL
	80 mM	0.0297 mL	0.1487 mL	0.2973 mL	0.7433 mL
	100 mM	0.0238 mL	0.1189 mL	0.2378 mL	0.5946 mL

Keywords

Morusin

14 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

Morusin

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Kinase Inhibitor Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Small Molecule Immuno-Oncology Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Antibacterial Compound Library

Medicine Food Homology Compound Library

Phenols Library

Pyroptosis Compound Library

Traditional Chinese Medicine Active Compound Library

Flavonoids Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Food-Sourced Compound Library

Anti-Liver Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Highly Selective Inhibitors Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Posttranslational Modification Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Morusin

Ver todos los productos específicos de isoformas NF-κB

Ver todos los productos específicos de isoformas STAT

Actividad biológica

Chemical Information

Publications (14)

Solvente y solubilidad

Protocolo

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

Morusin Related Classifications

HY-N0622 Related Classifications